FIELD: medicine. SUBSTANCE: remedy has prostaglandin E1 dinitroglycerate as primary agent. It is produced as hydrophilic polymer gel, containing prostaglandin E1 dinitroglycerate both in micellar and in polymer form. The remedy is applied on injured area surface as thin layer once or many times a day depending on nature of pathologic process. Local vascular dilatation, inhibition of platelet aggregation and increased regeneration processes are observed in injured area. EFFECT: enhanced effectiveness of treatment; excluded undesirable side effects. 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 1,3-DINITROGLYCEROL ESTERS OF POLYUNSATURATED FATTY ACIDS, HYDROXY-DERIVATIVES OF POLYUNSATURATED FATTY ACIDS AND PROSTAGLANDINS AND METHODS OF THEIR SYNTHESIS | 1993 |
|
RU2067094C1 |
| AGENT FOR TREATING CHRONIC OBLITERATING PERIPHERAL VASCULAR DISEASES BASED ON PROSTAGLANDIN | 2018 |
|
RU2695068C1 |
| PROSTAGLANDIN-BASED BRONCHOLYTIC DRUG | 2012 |
|
RU2500397C1 |
| PHARMACEUTICAL COMPOSITIONS FOR INHALATIONS CONTAINING NITROPROSTON | 2017 |
|
RU2662099C1 |
| PROSTAGLANDIN FALPHA DERIVATIVES FOR REDUCING INTRAOCULAR PRESSURE | 2018 |
|
RU2718744C2 |
| PROSTAMIDES AND THEIR ANALOGUES POSSESSING NEUROPROTECTIVE ACTION | 2011 |
|
RU2474426C1 |
| DERIVATIVES OF NON-STEROID ANTI-INFLAMMATORY AGENTS | 2018 |
|
RU2732297C2 |
| METHOD OF PRODUCING IMMOBILIZED PROSTAGLANDINE HAVING ANTIAGGREGATION ACTIVITY | 0 |
|
SU982695A1 |
| 2-CYCLOALKYLAMINO-5-THIENYL-1,3,4-THIADIAZINES, HYDROBROMIDES, WITH ANTIAGGREGANT ACTIVITY | 2008 |
|
RU2379306C1 |
| 1,3-DINITROGLYCEROL ESTER OF PROSTAGLANDIN )R 9-OXIME OF PROSTAGLANDIN SHOWING VASODILATING AND ANTIAGGREGATING ACTIVITIES | 0 |
|
SU1825786A1 |
